Carl Zeiss Meditec AG
Carl Zeiss Meditec AG increases share capital by up to 10%
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Capital Increase/Corporate Action Press Release NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Carl Zeiss Meditec AG increases share capital by up to 10% JENA, 21 March 2017 Carl Zeiss Meditec AG has resolved on a cash capital increase from authorized capital of up to 10% minus one share. In total up to 8,130,960 new shares will be offered to institutional investors by way of an accelerated bookbuilding process with the exclusion of subscription rights.
The Company plans to use the proceeds to accelerate its growth strategy. Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, states: “Given the current dynamics and consolidation trends in our markets, we see significant opportunities in the short to medium term to accelerate our growth through selective acquisitions. A number of projects in different size brackets are being considered, for which we aim to substantially increase our financial power and flexibility with the current transaction, improving our position for potential future acquisitions. We continuously aim to further expand our already very successful strategy as a global solutions provider in ophthalmology and microsurgery with additional growth initiatives.” The new shares will carry full dividend rights for the past fiscal year 2015/16 and will be offered for purchase exclusively to institutional investors in a private placement by way of an accelerated bookbuilding process, which starts immediately following publication of this press release. The Company reserves the right to close the order book at any time. Carl Zeiss AG will not subscribe for any shares in the contemplated capital increase. Thus, the free float will increase from 35% up to approximately 41% and thereby market liquidity of the Carl Zeiss Meditec AG share will be broadened. Carl Zeiss AG will remain a long-term majority shareholder in Carl Zeiss Meditec AG. Joh. Berenberg, Gossler & Co. KG and Commerzbank AG act as Joint Global Coordinators and Joint Bookrunners for the transaction.
Contact for media and investors Forward-Looking Statements Notice Brief profile The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries. For more information visit our website at: www.zeiss.com
21.03.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Carl Zeiss Meditec AG |
Göschwitzer Str. 51-52 | |
07745 Jena | |
Germany | |
Phone: | +49 (0)3641 220-0 |
Fax: | +49 (0)3641 220-112 |
E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com |
Internet: | www.meditec.zeiss.de |
ISIN: | DE0005313704 |
WKN: | 531370 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |